Search
Massachusetts Paid Clinical Trials
A listing of 3195 clinical trials in Massachusetts actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
2857 - 2868 of 3195
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Massachusetts is currently home to 3195 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Dilated Cardiomyopathy (DCM) Research Study
Recruiting
If you are identified as eligible for investigational genetic testing, you will be sent a saliva collection kit to your home. Once you have completed and returned your kit to Sano Genetics, your sample will be tested for a specific genetic pathway called BAG3.
Investigational genetic testing can help you better understand your body and its needs, as well as how DCM may be passed down in your family. Those who are identified as having a variant in the BAG3 gene will be referred to an upcoming clinical trial.
Investigational genetic testing can help you better understand your body and its needs, as well as how DCM may be passed down in your family. Those who are identified as having a variant in the BAG3 gene will be referred to an upcoming clinical trial.
Conditions:
Dilated Cardiomyopathy (DCM)
Cardiovascular Diseases
Cardiomyopathy
Cardiovascular Disease
Heart Failure
Featured Trial
Parkinson's Disease: Genetic Testing and Clinical Trial
Recruiting
Sano is launching a new study to understand the genetics of Parkinson’s and give researchers the data they need to better understand this condition. By participating, you will support cutting-edge research and help pave the way for future breakthroughs. You may be referred to participate in a clinical trial.
By participating in this study, you can:
- Receive a first-of-its-kind, Parkinson's genetic test at home, cost free
- Understand your eligibility for an investigational clinical trial in Parkinson's disease
- Receive notifications for future research opportunities
- Access expert, condition-specific educational materials tailored to Parkinson's disease
By participating in this study, you can:
- Receive a first-of-its-kind, Parkinson's genetic test at home, cost free
- Understand your eligibility for an investigational clinical trial in Parkinson's disease
- Receive notifications for future research opportunities
- Access expert, condition-specific educational materials tailored to Parkinson's disease
Conditions:
Parkinson's Disease
Parkinson Disease
Parkinson's Disease (PD)
Idiopathic Parkinson's Disease
Parkinsonian Disorders
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Video Images About Decisions for Ethical Outcomes in the Emergency Department (VIDEO-ED)
Recruiting
A randomized controlled trial of a video decision aid in the Emergency Department Setting to improve advance care planning documentation.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/18/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Emergencies
Postoperative VR for Recovery After Bariatric Surgery
Recruiting
The objective of this study is to investigate whether the addition of immersive virtual reality (VR) in the immediate postoperative period to an enhanced recovery after surgery (ERAS) protocol could improve postoperative recovery from bariatric surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Bariatric Surgery Candidate, Postoperative Pain, Postoperative Complications
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
Recruiting
The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism).
Gender:
ALL
Ages:
All
Trial Updated:
03/18/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome, Clonal Hematopoiesis, Mosaicism
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
Recruiting
This research study evaluates the effect of chemotherapy on cognition (thinking) and the brain in people with breast cancer.
Gender:
FEMALE
Ages:
60 years and above
Trial Updated:
03/18/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
Recruiting
This research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast cancer.
The names of the study interventions involved in this study are:
* Radiation Therapy (RT)
* Immunotherapy: Pembrolizumab (MK-3475)
* Chemotherapies:
* Paclitaxel
* Doxorubicin (also called Adriamycin)
* Cyclophosphamide
* Carboplatin (optional, and in TN onl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
Sacituzumab Govitecan In TNBC
Recruiting
This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC)
The names of the study drugs involved in this study is:
* Sacituzumab govitecan (SG)
* Pembrolizumab (combination therapy with SG)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
Recruiting
This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient.
This study is an open label trial in which Letermovir will be prescribed to prevent the recurrence of CMV infection and disease in a solid organ transplant recipient following treatment of CMV infection or disease.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/15/2024
Locations: Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases, Boston, Massachusetts
Conditions: Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients, Neutropenia, Antiviral Toxicity
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Recruiting
This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Melanoma, Squamous Cell Carcinoma of Head and Neck
Immune and Genomic Markers in ALK+ NSCLC
Recruiting
The purpose of this research study is to obtain and study clinical history, and tissue and saliva specimens if available from participants with Anaplastic Lymphoma Kinase-ALK+ Non-Small Lung Cancer(NSCLC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Anaplastic Lymphoma Kinase Gene Translocation, Non-Small Cell Lung Cancer
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Boston, Massachusetts
Conditions: Neoplasms
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
Recruiting
The goal of this prospective study to investigate the use of circulating tumor DNA (ctDNA) to guide end of therapy decisions in patients with melanoma or non-small-cell lung cancer.
The main question it aims to answer is:
• Do patients with metastatic melanoma or non-small-cell lung cancer, who have received at least 12 months of immune checkpoint inhibition (monotherapy or in combination) with evidence of disease response/control on imaging and have no evidence of circulating tumor DNA, have... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Melanoma, Non-small Cell Lung Cancer
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
Recruiting
This study aims to understand the use of continuous glucose monitors (CGM) in Asian Americans with type 2 diabetes (T2D). Researchers will compare participants on continuous glucose monitors with participants using fingerstick self-monitoring with the aim of answering the following questions:
1. Check if continuous glucose monitoring is doable and consistent for this group, and see how it affects their quality of life.
2. Estimate how well the health outcomes (glucose and lipid markers) vary ov... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/14/2024
Locations: Joslin Diabetes Center, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2